SynAct Pharma narrows Q3 net loss as operating expenses fall 15%
Sweden's SynAct Pharma reported a smaller Q3 net loss as operating expenses fell 15% year on year, with cash runway now reaching into Q4 2027.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Swedish biotech SynAct Pharma reported a narrower net loss for the third quarter, as operating expenses dropped 15% from a year earlier to SEK 30.09 million. The net loss came to SEK 32.18 million, the adjusted loss per share was SEK 0.57, and operating cash flow was negative at SEK -18.71 million. Reuters reported the figures, citing company data and LSEG.
The company said further analysis of the ADVANCE study data clarified the Phase 3 trial design for resomelagon in rheumatoid arthritis. It expects FDA feedback on that design by the end of 2026 or in early 2027. After the quarter closed, SynAct signed its first commercial partnership for resomelagon, and it said its cash runway extends into Q4 2027 and beyond key milestones.
why it matters
For the market this is a single-company story: SynAct remains a small biotech issuer, and its shares will hinge on partnering talks and the regulator's view of the trial design. Reuters noted that Wall Street's median 12-month price target is SEK 30.00, about 85.9% above the November 2 close of SEK 16.14, but that is an analyst view, not a company statement.
tags
instruments
sources
- Sweden's SynAct Pharma Q3 net loss narrows as expenses fall — Reuters, 3 November 2026 at 06:40 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗